Ifebemtinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ifebemtinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ifebemtinib can convert its Small molecule drug profile and FAK biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ifebemtinib (query alias: Ifebemtinib) |
|---|---|
| Modality / target | Small molecule drug; FAK; FAK inhibitors |
| Highest global status | Phase 3 |
| Originator | Boehringer Ingelheim GmbH |
| Active developers | Inxmed (Shanghai) Co., Ltd, Yingshi Biotechnology (Shenzhen) Co., Ltd. |
The MCP disease footprint includes KRAS G12C mutant non-squamous non-small cell lung cancer, Non-squamous non-small cell lung cancer, Recurrent Platinum-Resistant Ovarian Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07174908 | Phase 3 | Recruiting | 400 | Progression-Free Survival (PFS) |
| NCT07441174 | Phase 1/2 | Recruiting | 92 | Phase Ib:Recommended phase II dose (RP2D) of IN10018 in combination with RNK08954 |
| NCT06946927 | Phase 1 | Recruiting | 72 | Recommended Phase II dose (RP2D) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Safety and efficacy of ifebemtinib combined with garsorasib in KRAS G12C mutant colorectal cancer from a randomized part of a phase Ib/II study.
Phase 1/2; n=36; evaluation: Positive. Reported fields: DCR = 77.8 % ( 52.4 - 93.6); DCR = 100.0 % ( 81.5 - 100.0)
Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS<sup>G12C</sup> mutant solid tumors from a phase Ib/II study: 2-year follow-up from single-arm of non-small-cell lung cancer (NSCLC).
Phase 1/2; n=33; evaluation: Positive. Reported fields: -; SAE = 33.3 % ; -
Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) and randomized part of colorectal cancer (CRC).
Phase 1/2; n=not disclosed; evaluation: Positive. Reported fields: -; PFS(12-month) = 67.9 % ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ifebemtinib addresses KRAS G12C mutant non-squamous non-small cell lung cancer, Non-squamous non-small cell lung cancer, Recurrent Platinum-Resistant Ovarian Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-05-08 | 复星医药与应世生物达成战略合作 获两款肿瘤创新FAK抑制剂独家商业化权益 | Phase 1 | Financial terms not disclosed |
| 2022-10-19 | 应世生物与华奥泰宣布达成联合研发战略合作 | Phase 2 | Financial terms not disclosed |
| 2020-05-22 | Alphamab Oncology and InxMed Announce Partnership to Develop Combination Therapy of KN046 and IN10018 | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
